Lundelin Krista, Poussa Tuija, Salminen Seppo, Isolauri Erika
Department of Paediatrics, Turku University Hospital, Turku, Finland.
Department of Clinical Sciences, Faculty of Medicine, University of Turku, Turku, Finland.
Pediatr Allergy Immunol. 2017 Mar;28(2):170-175. doi: 10.1111/pai.12675. Epub 2016 Dec 23.
Societies worldwide are faced with a progressive increase in immune-mediated health problems such as allergic, autoimmune, and inflammatory diseases, as well as obesity. Perinatal administration of specific probiotic bacteria is an attractive approach in reducing the risk of these conditions, but long-term efficacy and safety data are lacking. The aim here was to evaluate the clinical benefit and long-term safety of specific probiotics administered during the perinatal period.
The probiotic strains used were Lactobacillus rhamnosus GG, Bifidobacterium lactis Bb-12, Lactobacillus paracasei ST11, and Bifidobacterium longum BL999. The children involved have subsequently undergone prospective long-term follow-up. In addition to physical examination, data were collected by structured questionnaires on non-communicable diseases and continued probiotic use, and growth data from welfare clinics and school nurses.
Altogether 303 mother-infant pairs were included in the analysis. Seventy-six of 163 (47%) children receiving perinatal probiotics had developed allergic disease compared with 79 of 140 (56%) receiving placebo (OR 0.67, 95% confidence intervals [CI] 0.43-1.06, p = 0.09). Fifty-nine of 133 (44%) children receiving L. rhamnosus GG perinatally had developed allergic disease, OR 0.62, 95% CI 0.38-0.99, p = 0.047, as compared to placebo. We found no differences in growth or non-communicable disease prevalence between children receiving perinatally probiotics or placebo.
Perinatal probiotic administration is safe in long-term follow-up. Children receiving L. rhamnosus GG perinatally tended to have decreased allergy prevalence.
全球社会面临着免疫介导的健康问题逐渐增加的情况，如过敏性疾病、自身免疫性疾病、炎症性疾病以及肥胖症。围产期给予特定益生菌是降低这些疾病风险的一种有吸引力的方法，但缺乏长期疗效和安全性数据。本研究的目的是评估围产期给予特定益生菌的临床益处和长期安全性。
使用的益生菌菌株为鼠李糖乳杆菌GG、乳酸双歧杆菌Bb-12、副干酪乳杆菌ST11和长双歧杆菌BL999。所涉及的儿童随后接受了前瞻性长期随访。除了体格检查外，还通过关于非传染性疾病和持续使用益生菌的结构化问卷收集数据，以及从福利诊所和学校护士处收集生长数据。
总共303对母婴纳入分析。163名接受围产期益生菌的儿童中有76名（47%）患过敏性疾病，而接受安慰剂的140名儿童中有79名（56%）患过敏性疾病（比值比[OR]0.67，95%置信区间[CI]0.43 - 1.06，p = 0.09）。围产期接受鼠李糖乳杆菌GG的133名儿童中有59名（44%）患过敏性疾病，与安慰剂相比，OR为0.62，95%CI为0.38 - 0.99，p = 0.047。我们发现接受围产期益生菌或安慰剂的儿童在生长或非传染性疾病患病率方面没有差异。
围产期给予益生菌在长期随访中是安全的。围产期接受鼠李糖乳杆菌GG的儿童过敏性疾病患病率有降低的趋势。
